The healthcare and pharmaceuticals sector is evolving rapidly, driven by innovation in treatment modalities, shifting regulatory frameworks, and global demand for equitable care. We help deliver strategic insights across the product lifecycle—from early-stage R&D to market entry and long-term growth planning. Our services enable clients to prioritize opportunities, de-risk development, optimize launch timing, and expand access. By combining robust data analytics with clinical and commercial expertise, we help organizations make informed, data-driven decisions in dynamic markets.
HOW WE HELP OUR CLIENTS IN THIS SECTOR
Market Forecasting and Demand Estimation
We support healthcare organizations, ranging from global pharma and medtech firms to emerging biotechs and investors, in navigating uncertainty through evidence-based market sizing and demand forecasting solutions. Our consulting-led approach integrates macroeconomic variables, disease burden, treatment adoption rates, pricing benchmarks, demand trends, competitive analysis, regulatory frameworks, and investment signals to develop actionable forecasts. These models inform critical decisions related to portfolio investments, go-to-market strategy, regional expansion, and long-term strategic planning.
- Market Opportunity Sizing – Quantify the total, serviceable, and addressable market across geographies, patient segments, and product categories
- Scenario-Based Demand Forecasting – Modelling demand trajectories based on disease prevalence, treatment adoption, technology penetration, and care delivery shifts
- Pricing & Reimbursement Landscape Analysis – Evaluate current and projected pricing bands, cost structures, and payer dynamics
- Funding and Investment Analysis - Tracking funding flows and investment activity across public, private, and strategic channels
- Competitor Benchmarking - Analyzing competitive dynamics through market share assessments, investment activity, and potential disruption from new entrants or adjacent technologies
Prioritizing Emerging Markets for Oncology Launches
Designing a Multi-Parameter Oncology Demand Framework Across High-Potential MarketsA global pharmaceutical firm, seeking to expand its oncology portfolio in emerging economies, engaged us to build a data-driven model for prioritizing market entry. We developed a comprehensive forecasting framework covering ten geographies, incorporating variables such as cancer incidence and mortality rates, therapy adoption benchmarks, treatment infrastructure availability, payer mix, and historical sales data. The analysis was segmented by tumor type, line of therapy, and administration route, enabling a granular assessment of demand maturity and future potential. We also analyzed regulatory timelines and health financing mechanisms to determine commercial readiness and identify friction points in access pathways.
Strategic Market Sequencing and Cross-Functional Resource AllocationOur insights informed the client’s strategic roadmap by identifying countries with favorable regulatory conditions, emerging demand for targeted therapies, and accelerating public investment in oncology care. We outlined market entry sequencing based on size, speed, and ease of penetration, while flagging country-specific commercial considerations such as reimbursement timelines, pricing corridors, and local prescribing behaviors. The findings enabled regional and functional alignment across market access, commercial, and regulatory teams. As a result, the client recalibrated its launch order, secured early buy-in from affiliates, and reduced its go-to-market time in prioritized regions.
Sizing the Radiotherapy Patient Positioning Accessories Market
Defining the Market Landscape for Positioning SolutionsA leading medical device manufacturer approached us to evaluate the standalone market opportunity for patient positioning accessories in radiotherapy components like immobilization masks, headrests, fixation boards, and body cradles. While traditionally bundled with linear accelerators, the client sought to decouple this segment and explore independent market capture. We constructed a market sizing model across North America, Europe, and Asia-Pacific, integrating radiotherapy procedure volume data, cancer type distribution, equipment replacement cycles, and care setting dynamics. The model accounted for product-specific wear-out rates, differences in clinical workflows, and localized sterilization and procurement protocols. This helped quantify total addressable demand and identify high-value product segments suitable for an independent commercial strategy.
Informing Product Customization, Pricing, and Market Penetration StrategiesThe findings guided the client in refining their product development roadmap, emphasizing features aligned with clinical needs and operational efficiencies. We evaluated import regulations, sterilization compliance needs, and site-level procurement cycles, which informed localized pricing strategies and sales enablement tools. These findings shaped investments in product design modifications and supported the development of a differentiated value proposition for public hospitals, private clinics, and academic cancer centers. As a result, the client successfully decoupled the accessories portfolio from equipment sales and expanded its market footprint across high-opportunity radiotherapy markets.
Drug Pipeline Assessment
We help clients assess the competitive and scientific landscape across therapeutic areas by evaluating pipeline dynamics—from discovery through regulatory approval. Our team builds structured visibility into emerging mechanisms of action, trial strategies, sponsor behavior, and development risk. These insights guide R&D portfolio reviews, identify whitespace opportunities, and inform co-development, licensing, and M&A pathways.
- End-to-End Pipeline Mapping – Track investigational assets across preclinical, clinical, and regulatory phases with segmentation by geography, sponsor, and modality
- Innovation Gap Analysis – Identify over-saturated targets and unmet needs by benchmarking mechanisms, endpoints, and patient subgroups
- Regulatory Acceleration & Risk Assessment – Monitor trial success rates, orphan designations, and fast-track approvals to inform timing and positioning
- Analyzing Post-Approval Activities – Including Phase IV studies, label expansions, and pharmacovigilance efforts
- Strategic Opportunity Identification – Evaluating licensing and collaboration trends across stages to inform strategic partnering, M&A, or out-licensing opportunities
Tracking Competitive Development to Guide R&D Investments
Mapping Pipeline Activity to Benchmark Innovation and Portfolio SaturationA mid-sized biopharmaceutical company sought to evaluate the innovation trajectory and competitive saturation within its core therapeutic area. We developed a comprehensive pipeline tracker covering assets across preclinical through Phase IV development stages, segmented by indication, mechanism of action, sponsor type, and geography. The analysis also included benchmarking on trial design complexity, attrition rates, regulatory acceleration markers (e.g., Fast Track, Breakthrough Designation), and clinical clustering around academic research hubs. These insights offered a high-resolution view of therapeutic momentum, emerging targets, and the evolution of clinical strategy in the space.
Informing Risk-Adjusted R&D Strategy and Portfolio RealignmentOur report served as a foundational input into the client's R&D prioritization exercise, supporting evidence-based decisions on resource reallocation. By quantifying asset concentration across specific subpopulations and comparing clinical design trajectories, we helped the client identify saturated zones with limited differentiation potential and under-explored areas with high unmet need. The findings also supported co-development deal structuring and improved internal visibility into pipeline competitiveness, enabling senior leadership to make timely go/no-go decisions based on clear development intelligence, rather than speculative assumptions.
Supporting Strategic Planning in Adjacent Therapeutic Areas
Identifying Early-Stage Development Activity Beyond Core IndicationsA global healthcare major exploring expansion into adjacent therapeutic areas engaged us to provide visibility into early-stage innovation beyond their current portfolio. We mapped pipeline activity across shortlisted adjacent indications, focusing on preclinical and Phase I development. Our methodology combined traditional pipeline analysis with IP filing trends, academic licensing activity, seed-stage funding signals, and partnerships between companies and academic institutions. This approach helped detect early momentum around specific targets, delivery platforms, and biological pathways—well ahead of market saturation or commercial visibility.
Developing Roadmaps and Partnership Pathways for EntryThe analysis was used by the client’s strategy and business development teams to identify under-the-radar innovation with limited development overlap and high licensing potential. For the highest-potential targets, we modeled clinical feasibility, licensing readiness, and projected development costs. We also profiled promising innovators for potential co-development or in-licensing deals. These insights directly informed the client’s expansion plan over a 3–5-year horizon and supported early-stage portfolio committee discussions. The report also informed early-stage partnering strategy and helped internal teams identify high-fit assets for in-licensing, acquisition, or collaboration discussions.
Epidemiology Forecast Reports
We support clinical-stage companies, commercial teams, and investors with robust, decision-grade epidemiology models tailored to therapeutic and strategic objectives. Our modeling helps clients understand the current and projected burden of diseases across geographies, stratified by clinically and commercially relevant segments. These forecasts support trial feasibility, launch readiness, pricing models, and rare disease investments with a focus on real-world applicability and stakeholder alignment.
- Patient Population Estimation – Delivering multi-year disease burden forecasts including total, diagnosed, and treatable patient pools across base and forecast years
- Subgroup Stratification – Segment populations by genotype, biomarker, disease stage, age, and comorbidity to support targeted trial design
- Patient Journey & Flow Analysis – Map progression from prevalence to diagnosis, treatment initiation, and long-term outcomes
- Regional & Site-Level Forecasting – Generate national and sub-national estimates to inform site feasibility and access planning
- Rare Disease Opportunity Modeling – Forecast future addressable populations based on diagnostic expansion, screening programs, and clinical advancement
Supporting Trial Design with Precision Patient Modelling
Generating Target Population Estimates for Clinical PlanningA clinical-stage biotech firm developing an immunotherapy for a rare solid tumor approached us to quantify its target patient population across multiple global markets. We developed a custom epidemiology model estimating prevalence, incidence, diagnosis rates, and eligibility alignment with the trial’s inclusion/exclusion criteria. The model stratified patients by age, gender, stage of disease, diagnostic access, and treatment status, using inputs from literature, cancer registries, and validated secondary datasets. A 10-year horizon was applied to project patient pool growth, particularly in regions undergoing expansion in diagnostics and treatment accessibility.
Optimizing Recruitment Feasibility and Geographic Site StrategyThe findings enabled the client's clinical operations team to develop an evidence-based enrolment strategy that matched real-world eligibility conditions. Using sub-national prevalence data, we identified recruitment hotspots and flagged geographies where diagnostic underpenetration could delay enrolment. These insights were used to align site-level targets, adjust protocol screening expectations, and engage early with local investigators. The model also supported submission materials for regulatory bodies and ethics committees, offering a robust rationale for proposed enrolment numbers and site distribution. As a result, the client was able to reduce screen failure rates and improve first-patient-in timelines across multiple trial regions.
Validating Market Opportunity in Rare Disease Investment
Forecasting Long-Term Patient Volumes for High-Risk Asset EvaluationAn investment firm evaluating entry into the rare disease space sought robust epidemiological evidence to assess the commercial viability of a gene therapy candidate in a metabolic disorder. We provided 15-year epidemiological forecast across the US, EU5, and Japan, segmented by genotype, age of onset, and diagnostic accessibility. The model incorporated registry data, published prevalence studies, and diagnostic expansion trends to define the current and future addressable populations.
Strengthening Investor Confidence and Enabling Portfolio EntryThe analysis enabled the client to validate key commercial assumptions such as peak patient reach, expected penetration timelines, and long-term revenue potential. Scenario planning was built into the model, enabling sensitivity testing across screening uptake, diagnostic rate acceleration, and payer adoption. These outputs were integrated into valuation models and internal investment committee presentations. The epidemiology forecast was also used in external communications with co-development partners and strategic buyers, strengthening the investment case.
Technology and Patent Analysis
We advise clients on navigating complex IP landscapes across pharmaceuticals, biologics, diagnostics, and devices. Our patent analysis services help assess exclusivity duration, freedom to operate, portfolio defensibility, and litigation risk—critical inputs for launch strategy, investment evaluation, and lifecycle management. Our consulting frameworks translate legal complexity into strategic clarity, enabling proactive decision-making across commercial and legal functions.
- Patent Landscape Mapping – Identify core and secondary patents across target jurisdictions, technologies, and claim types
- Exclusivity Timeline Analysis – Analyzing patent expiry timelines, including compound patent cliffs, SPCs (Supplementary Protection Certificates), and PTEs (Patent Term Extensions) to identify launch windows and exposure risks
- Freedom-to-Operate Assessment – Evaluate barriers to entry and highlight workarounds or design-arounds in crowded IP spaces
- Litigation & Legal Risk Monitoring – Track oppositions, invalidation proceedings, and inter partes reviews to assess portfolio vulnerability
- Licensing and IP Monetization Strategy – Support out-licensing, asset acquisition, or valuation through defensibility and coverage analysis
Evaluating Exclusivity Timelines to Guide Launch Strategy
Assessing Global Patent Exposure and Exclusivity PathwaysA pharmaceutical company preparing for the launch of a competitive formulation in the small molecule oncology segment approached us to assess the intellectual property landscape surrounding the reference product. We conducted a multi-jurisdictional patent analysis covering composition-of-matter, formulation, method-of-use, and secondary patent families across the US, EU, and APAC regions. Our team mapped legal statuses, expiry timelines, supplementary protection certificates (SPCs), patent term extensions (PTEs), and exclusivity designations (e.g., Orphan Drug, New Chemical Entity). We also reviewed litigation history, oppositions, and ongoing appeals to evaluate potential roadblocks to generic entry.
Supporting Commercial Launch Planning and Legal Risk MitigationOur analysis informed the client’s regulatory and legal teams on market-specific risk profiles, enabling them to prioritize filings and plan tactical mitigation strategies in high-risk regions. Commercial teams used the expiry forecast model to align promotional and sales activities with potential entry windows, particularly in markets with expiring SPCs or limited post-grant legal activity. This alignment facilitated timely resource deployment and reduced delays in sales activation. The findings also fed into board-level go/no-go decisions, helping the client de-risk exposure and secure timely access to high-value markets immediately following loss of exclusivity.
Supporting Tech Evaluation During Due Diligence
IP Landscape Review for Licensing CandidatesA healthcare-focused private equity firm engaged us during the due diligence phase of a licensing transaction involving multiple early-stage assets. We conducted a comprehensive IP assessment of each candidate, covering patent breadth, remaining exclusivity period, freedom-to-operate (FTO), and potential for design-around risk. We analyzed the enforceability and novelty of the claims, backward and forward citation histories, and prior art challenges to determine the strength of protection. Jurisdictional spread and family size were evaluated to determine the robustness of global market protection and litigation exposure.
Informing Licensing Decisions and Negotiation LeverageThe findings allowed the client to rank candidates based on IP defensibility and strategic alignment with their commercial goals. Assets with narrow or poorly prosecuted patents, pending oppositions, or unproven innovation claims were deprioritized. For high-value candidates, our IP scoring system highlighted areas for negotiation leverage, particularly where exclusivity runway was shorter than industry benchmarks. The client ultimately shortlisted three assets and proceeded with two licensing agreements backed by stronger IP positioning. Our insights helped them avoid costly post-deal surprises and build a licensing portfolio anchored in enforceable, scalable innovation.
Market Insights
Insights that foster growth and research that drives revolution for your business. Our collaboration is all we need to dive into the immense possibilities of your business.
Consumer Insights
The most appropriate strategies for you to get comprehensive insights right into your target market.
Competitive Benchmarking
Get the most elaborate analysis of your competitors to get the competitive edge.
MI 360
Get quick access to comprehensive market insights with clarity (insight-heavy) and brevity (not text-heavy)!
Business Plans
Get fool-proof business plans backed with rigorous research, extensive evaluation, and accurate analysis.
Our Core Performance Metrics
When it comes to delivery, the quality of your projects is non-negotiable. We ensure we don’t have any room left for a subpar quality.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
